• 2025免费加速神器-outline

    2025免费加速神器-outline

    w加速任天行安卓版

    Luis
    Supply Chain at Apellis

    2025免费加速神器-outline

    Learn More
    Folded page of a newspaper

    2025免费加速神器-outline

    2025免费加速神器-outline

    Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

    2025免费加速神器-outline

    ET官网-http伟理ip软件网络加速器_免费ip伟理服务器_爬虫 ...:2021-7-4 · 伟理ip软件首选ET伟理,是国内伢质http伟理动态IP服务商,ET伟理服务器拥有26个省千万级动态ip地址,提供换ip软件免费ip伟理,网络加速器,socks5伟理,爬虫服务器,ip加速器等伟理池供应服务。

    July 2, 2025

    Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Newsroom
    w加速任天行安卓版

    @ApellisPharma

    A man with a baby in a baby carrier

    2025免费加速神器-outline

    FOR PATIENTS
    Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

    2025免费加速神器-outline

    for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
    C3 glomerulopathy, and cold agglutinin disease.

    PIPELINE
    3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

    2025免费加速神器-outline

    are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.

    CLINICAL TRIALS

    2025免费加速神器-outline

    so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike

    We challenge conventional thinking and always question if there's a better way.

    Join Us
    w加速任天行安卓版

    Patricia
    Quality Assurance at Apellis